Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2009 | Original Article

Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with ⁶⁴Cu-DOTA-trastuzumab

Authors: Gang Niu, Zibo Li, Qizhen Cao, Xiaoyuan Chen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2009

Abstract

Purpose

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat-shock protein 90 (Hsp90) inhibitor, has been intensively investigated for cancer therapy and is undergoing clinical trials. Human epidermal growth factor receptor 2 (HER-2) is one of the client proteins of Hsp90 and its expression is decreased upon 17-DMAG treatment. In this study, we aimed to noninvasively monitor the HER-2 response to 17-DMAG treatment in xenografted mice.

Methods

The sensitivity of human ovarian cancer SKOV-3 cells to 17-DMAG in vitro was measured by MTT assay. HER-2 expression in SKOV-3 cells was determined by flow cytometry. Nude mice bearing SKOV-3 tumors were treated with 17-DMAG and the therapeutic efficacy was evaluated by tumor size measurement. Both treated and control mice were imaged with microPET using ⁶⁴Cu-DOTA-trastuzumab and ¹⁸F-FDG. Biodistribution studies and immunofluorescence staining were performed to validate the microPET results.

Results

SKOV-3 cells are sensitive to 17-DMAG treatment, in a dose-dependent manner, with an IC₅₀ value of 24.72 nM after 72 h incubation. The tumor growth curve supported the inhibition effect of 17-DMAG on SKOV-3 tumors. Quantitative microPET imaging showed that ⁶⁴Cu-DOTA-trastuzumab had prominent tumor accumulation in untreated SKOV-3 tumors, which was significantly reduced in 17-DMAG-treated tumors. There was no uptake difference detected by FDG PET. Immunofluorescence staining confirmed the significant reduction in tumor HER-2 level upon 17-DMAG treatment.

Conclusion

The early response to anti-Hsp90 therapy was successfully monitored by quantitative PET using ⁶⁴Cu-DOTA-trastuzumab. This approach may be valuable in monitoring the therapeutic response in HER-2-positive cancer patients under 17-DMAG treatment.

Jakob U, Lilie H, Meyer I, Buchner J. Transient interaction of Hsp90 with early unfolding intermediates of citrate synthase. Implications for heat shock in vivo. J Biol Chem. 1995;270:7288–94. doi:10.1074/jbc.270.13.7288.PubMedCrossRef

Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A. 1996;93:8379–83. doi:10.1073/pnas.93.16.8379.PubMedCrossRef

Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125–33. doi:10.1038/sj.onc.1203753.PubMedCrossRef

Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530–6.PubMed

Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002;8:986–93.PubMed

Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159–66. doi:10.1038/sj.onc.1205184.PubMedCrossRef

Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111–33.

Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976–8. doi:10.1126/science.2992090.PubMedCrossRef

Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199–205.PubMed

10.

Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW. HER-2/neu oncogene expression and proliferation in breast cancers. Am J Pathol. 1990;137:103–11.PubMed

11.

Wiercioch R, Balcerczak E, Byszewska E, Mirowski M. Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma. Nucl Med Rev Cent East Eur. 2003;6:99–103.PubMed

12.

Traish AM, Wotiz HH. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 1987;121:1461–7.PubMedCrossRef

13.

Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol. 1997;7:1002–5. doi:10.1007/s003300050240.PubMedCrossRef

14.

Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 2002;21:2407–17. doi:10.1093/emboj/21.10.2407.PubMedCrossRef

15.

Murakami Y, Mizuno S, Uehara Y. Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells. Biochem J. 1994;301(Pt 1):63–8.PubMed

16.

Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 1999;91:1940–9. doi:10.1093/jnci/91.22.1940.PubMedCrossRef

17.

Silcox CE, Smith RC, King R, McDannold N, Bromley P, Walsh K, et al. MRI-guided ultrasonic heating allows spatial control of exogenous luciferase in canine prostate. Ultrasound Med Biol. 2005;31:965–70. doi:10.1016/j.ultrasmedbio.2005.03.009.PubMedCrossRef

18.

Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377–83. doi:10.2174/1568009033481831.PubMedCrossRef

19.

Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res. 2008;14:8302–7. doi:10.1158/1078-0432.CCR-08-1002.PubMedCrossRef

20.

Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, et al. A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543–6. doi:10.1007/s10637-006-9208-z.PubMedCrossRef

21.

Barzilay E, Ben-Califa N, Supino-Rosin L, Kashman Y, Hirschberg K, Elazar Z, et al. Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity. J Biol Chem. 2004;279:6847–52. doi:10.1074/jbc.M312799200.PubMedCrossRef

22.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 2007;6:1123–32. doi:10.1158/1535-7163.MCT-06-0628.PubMedCrossRef

23.

Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;51:34–41. doi:10.1002/pbc.21508.PubMedCrossRef

24.

Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R D 2008;9:351–68. doi:10.2165/0126839-200809060-00002.PubMedCrossRef

25.

McManus DT, Patterson AH, Maxwell P, Humphreys MW, Anderson NH. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol. 1999;52:75–7. doi:10.1136/mp. 52.2.75.PubMedCrossRef

26.

Stomper PC, Budnick RM, Stewart CC. Use of specimen mammography-guided FNA (fine-needle aspirates) for flow cytometric multiple marker analysis and immunophenotyping in breast cancer. Cytometry 2000;42:165–73. doi:10.1002/1097-0320(20000615) 42:3<165::AID-CYTO2>3.0.CO;2-7.PubMedCrossRef

27.

Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol. 2006;11:199–208. doi:10.1007/s10147-006-0575-4.PubMedCrossRef

28.

Thrall JH. Personalized medicine. Radiology 2004;231:613–16. 10.1148/radiol.2313040323.PubMedCrossRef

29.

Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11:117–27. doi:10.1007/BF00918679.PubMedCrossRef

30.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285–9. doi:10.1073/pnas.89.10.4285.PubMedCrossRef

31.

Bulte JWM, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17:484–99. doi:10.1002/nbm.924.PubMedCrossRef

32.

Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007;13:95–9. doi:10.1038/nm1467.PubMedCrossRef

33.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol. 2004;143:99–106. doi:10.1038/sj.bjp.0705915.PubMedCrossRef

34.

Niu G, Cai W, Chen K, Chen X. Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol. 2008;10:99–106. doi:10.1007/s11307-007-0123-2.PubMedCrossRef

35.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–9. doi:10.1158/0008-5472.CAN-05-1182.PubMedCrossRef

36.

Lang W, Caldwell GW, Li J, Leo GC, Jones WJ, Masucci JA. Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab Dispos. 2007;35:21–9. doi:10.1124/dmd.106.009639.PubMedCrossRef

37.

Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 2006;66:9673–81. doi:10.1158/0008-5472.CAN-06-1480.PubMedCrossRef

38.

Gossett DR, Bradley MS, Jin X, Lin J. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gynecol Oncol. 2005;96:381–8. doi:10.1016/j.ygyno.2004.10.009.PubMedCrossRef

39.

Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56:115–25. doi:10.1007/s00280-004-0939-2.PubMedCrossRef

40.

Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–78.PubMed

41.

Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41–5. doi:10.1038/47412.PubMedCrossRef

42.

Turner BM. Cellular memory and the histone code. Cell 2002;111:285–91. doi:10.1016/S0092-8674(02) 01080-2.PubMedCrossRef

43.

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–6. doi:10.1038/nbt968.PubMedCrossRef

44.

Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006;47:793–6.PubMed

45.

Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178–86. doi:10.1158/0008-5472.CAN-06-2887.PubMedCrossRef

46.

Bernier J. Drug insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol. 2008;5:705–13.PubMedCrossRef

47.

Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, et al. A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther. 2008;7:1630–40. doi:10.1158/1535-7163.MCT-07-2409.PubMedCrossRef

48.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol. 2007;25:5410–7. doi:10.1200/JCO.2007.11.7960.PubMedCrossRef

Title: Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab
Authors: Gang Niu
Zibo Li
Qizhen Cao
Xiaoyuan Chen
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1158-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with ⁶⁴Cu-DOTA-trastuzumab

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2009

Commentary on: Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging

Staging primary head and neck cancers with 18F-FDG PET/CT: is intravenous contrast administration really necessary?

[18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology

Incidental head and neck 18F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development?

Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients